Skip to main content
. 2022 Apr 12;14(4):845. doi: 10.3390/pharmaceutics14040845

Figure 7.

Figure 7

MC3T3-E1 pre-osteoblast exposure to HBGN for 3 d: (A) HBGN internalization obtained by intracellular complexity values (SSC), (B) viability evaluated by the exclusion of PI positive cells, (C) pre-osteoblast populations with ROS intracellular content (%) and (D) intensity of DCFH fluorescence, indicative of intracellular ROS content. * Indicates significant differences when p value < 0.05 was obtained.